RESEARCH OVERVIEW
What is PT-141?
PT-141 is the development name associated with bremelanotide, a cyclic melanocortin-receptor agonist. Its literature includes clinical pharmacology, controlled trials and analyses of patient-reported outcomes. These publications describe specific pharmaceutical study preparations, not an interchangeable specification for a research vial.
PT-141 10 mg — product details
This listing is for PT-141 10 mg, product code JG-MIG-033. The 10 mg figure is the listed material quantity, not a recommended dose or a concentration. Review this strength’s label and matching batch record when planning a laboratory assay.
LISTED CONTENT
10 mg
PRODUCT CODE
JG-MIG-033
INTENDED USE
Laboratory research
Research focus and areas of interest
Melanocortin pharmacology
Early human studies measured pharmacokinetic and physiological responses to a defined PT-141 formulation. Those investigations help explain the scientific questions behind receptor agonism, while their monitored protocols remain distinct from laboratory-product use. [1]
Clinical endpoints and response interpretation
The RECONNECT trials and responder analyses used defined populations and standardised questionnaires. Statistical or clinically meaningful changes in a trial are tied to those endpoints and participants. They should not be restated as a general promise that an unrelated preparation improves sexual function. [2]
Safety and wider physiological research
A pooled clinical-development safety analysis reports adverse-event patterns, and early trials examined food-intake or body-weight endpoints. Safety reporting is part of interpreting the evidence; it should not be omitted while highlighting favourable findings. [3]
Evidence and limitations
A compound’s pharmaceutical-development literature does not confer medicine status, pharmaceutical equivalence or proven safety on this JGPEP+ material. References are educational context and do not provide a personal-use or administration protocol.
Scientific references describe the material and methods used by their authors. They do not certify this product’s purity, sterility, identity or suitability for a particular experiment. A related analogue, delivery system or combination is not automatically equivalent to the supplied peptide.
Technical identity and documentation
Literature identity: PT-141/bremelanotide, a cyclic melanocortin analogue. Confirm exact chemical form, terminal modifications and analytical identity from the batch record. Distinguish compound identity from the formulation of a regulated medicinal product.
For this product’s identity and batch results, visit the COA and documentation page or contact JGPEP+ with the product and batch numbers. Literature values should not replace a matching analytical certificate.
Storage and laboratory handling
Follow the product label and batch-specific supplier instructions. Confirm temperature, solvent compatibility, stability and any reconstitution requirements before use. Storage conditions reported for another supplier or a clinical formulation should not be applied automatically to this material.
Research references
Original studies and analytical papers are linked below. Study type is included so that laboratory models, clinical research and related-analogue evidence can be distinguished.
1. Early PT-141 clinical pharmacology. Rosen RC et al. 2004 Apr. International journal of impotence research. Human pharmacology study. PubMed PMID 14999221 · Publisher / DOI
2. Controlled phase-3 clinical investigations. Kingsberg SA et al. 2019 Nov. Obstetrics and gynecology. Randomised clinical trials. PubMed PMID 31599840 · Publisher / DOI
3. Pooled clinical-development safety data. Clayton AH et al. 2022 Feb. Journal of women’s health (2002). Pooled clinical safety analysis. PubMed PMID 35147466 · Publisher / DOI
4. Early food-intake and body-weight studies. Spana C et al. 2022 Jun. Diabetes, obesity & metabolism. Randomised clinical studies. PubMed PMID 35170192 · Publisher / DOI
5. Responder analysis of a phase-2b study. Althof S et al. 2019 Aug. The journal of sexual medicine. Secondary clinical-trial analysis. PubMed PMID 31277966 · Publisher / DOI
For laboratory research only. Not for human or veterinary consumption or administration. This information is scientific background, not medical advice or an administration guide.
Reviews
There are no reviews yet.